Assessing the usefulness of the francine needle in EBUS-TBNA

A Randomized phase II trial aimed to assess the usefulness of the francine needle in endobronchial ultrasound-guided transbronchial needle aspiration or biopsy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1032220388

Enrollment

Registered

2022-10-18

Start date

2022-10-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer lung cancer,

Interventions

Patients are received EBUS-TBNA or TBNB using these devices under randomised: A: Francine needle - Lancet needle B: Lancet needle - Francine needle

D001999

Bronchoscopy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with suspected primary lung cancer 2)Patients who are scheduled for endobronchial ultrasound-guided transbronchial needle aspiration or biopsy 3)Patients who are 20 years of age or older 4)Patients who are provided written informed consent

Exclusion criteria

Exclusion criteria: 1)Patients who have a history of treatment for lung cancer 2)Patients for whom bronchoscopy is contraindicated 3)Patients who are pregnant, within 28 days postpartum, or lactating 4)Patients who are judged by the investigator to be unsuitable for this study

Design outcomes

Primary

Measure	Time frame
Tissue area of each lymph node sample	—

Secondary

Measure	Time frame
Tumor percentage of each lymph node Rate of blood contamination in each lymph node Diagnostic concordance between Francine and Lancet needles Adverse events Success rate for biomarker test for each lymph node	—

Contacts

Public ContactJun Ikari

Chiba University Hospital

junikari@chiba-u.jp+81-43-222-2576

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026